m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02781)
Name
Nitrofurantoin
Synonyms
1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin; Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Fua Med; Fua-med; Fur-ren; Furabid; Furachel; Furadantin; Furadantin (TN); Furadantin Retard; Furadantina MC; Furadantine; Furadantine mc; Furadantine-MC; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Furophen T; Gerofuran; Ituran; Macpac; Macrobid; Macrobid (TN); Macrodantin; Macrodantin (TN); Macrodantina; Macrofuran; Macrofurin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; N-Toin; ND-3320; ND-7248; NITROFURANTION; NITROFURANTOIN MACROCRYSTALLINE; NITROFURANTOIN, MACROCRYSTALLINE; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitro Macro (TN); Nitrofur-C; Nitrofuradantin; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; Nitrofurantoina; Nitrofurantoina [DCIT]; Nitrofurantoine; Nitrofurantoine [INN-French]; Nitrofurantoinum; Nitrofurantoinum [INN-Latin]; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Ro-Antoin; Siraliden; Trantoin; Uerineks; Urantoin; Urantoin (TN); Urizept; Uro-Selz; Uro-Tablinen; Uro-tablineu; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Usaf ea-2; Welfurin; Zoofurin
    Click to Show/Hide
Status
Approved
Structure
Formula
C8H6N4O5
InChI
1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
InChIKey
NXFQHRVNIOXGAQ-YCRREMRBSA-N
PubChem CID
6604200
VARIDT Drug ID
DR00886
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Nitrofurantoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nitrofurantoin through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64. doi: 10.1124/mol.104.010439. Epub 2005 Feb 11.